Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 16/20 | 0.63 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964669 | 1.00 | TYMS (0.63) | TYMSQTRT1DYRK1AGAAMAPT | |
| SCHEMBL6653029 | 0.80 | TYMS (0.81) | TYMS | |
| SCHEMBL21089737 | 0.79 | NPC1 (0.44) | TYMSGAAMAPTNPSR1RXFP1 | |
| SCHEMBL29440611 | 0.79 | TYMS (0.63) | TYMSGAAMAPTNPSR1 | |
| SCHEMBL13102494 | 0.79 | TYMS (0.63) | TYMSQTRT1MAPT | |
| SCHEMBL30012731 | 0.79 | NPC1 (0.44) | TYMSGAAMAPTNPSR1RXFP1 | |
| SCHEMBL3226572 | 0.79 | TYMS (0.63) | TYMSGAAMAPTNPSR1 | |
| SCHEMBL6455624 | 0.78 | TYMS (1.00) | TYMS | |
| SCHEMBL25204007 | 0.76 | ALDH1A1 (0.58) | TYMSGAAMAPTNPSR1RXFP1 | |
| SCHEMBL4973391 | 0.76 | KDM4E (0.63) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12187706-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3911416-B1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| US-11597704-B2 | 2,4-diaminoquinazoline derivatives and medical uses thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2023-03-07 | — | — | US | disclosed |
| EP-4059924-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-21 | — | — | EP | disclosed |
| US-20220241402-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-08-04 | — | — | US | disclosed |
| EP-3759083-B1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF VIRUS INFECTIONS, CANCER OR ALLERGIES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-05-04 | — | — | EP | disclosed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089572-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2020255039-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| CN-111868040-A | 2, 4-diaminoquinazoline derivatives and medical uses thereof | 爱尔兰詹森科学公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150115-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2018086585-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
| EP-2270002-A1 | Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg (NL) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010146173-A1 | QUINAZOLINE DERIVATIVES AS HISTAMINE H4-RECEPT0R INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-12-23 | — | — | WO | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TYMS 1459/4885QTRT1 2278/4885DYRK1A 4866/4885 |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | TYMS 3478/4885QTRT1 1534/4885DYRK1A 128/4885 |
| US-12391675-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TYMS 1491/4885QTRT1 2128/4885DYRK1A 4868/4885 |
| US-12187706-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TYMS 1459/4885QTRT1 2278/4885DYRK1A 4866/4885 |
| US-20220241402-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND QUINAZOLINE DERIVATIVES | HAVCR2, IRF3, IFNG | TYMS 1963/4885QTRT1 3561/4885DYRK1A 2980/4885 |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | QDPR, PADI2, PEPD | TYMS 812/4885QTRT1 1647/4885DYRK1A 533/4885 |
| US-20220089572-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TYMS 1491/4885QTRT1 2128/4885DYRK1A 4868/4885 |
| US-11597704-B2 | 2,4-diaminoquinazoline derivatives and medical uses thereof | HRH4, HRH3, HNMT | TYMS 2770/4885QTRT1 1931/4885DYRK1A 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.